Vaxxas
Vaxxas is a biotechnology company focused on enhancing the performance of vaccines through its proprietary high-density microarray patch (HD-MAP) technology. The company aims to revolutionize vaccine delivery with needle-free, easy-to-administer, and thermostable solutions, targeting infectious diseases and oncology. With a strong pipeline of clinical trials and collaborations with global organizations, Vaxxas is advancing toward commercialization of its innovative vaccine platform.
Industries
Nr. of Employees
medium (51-250)
Vaxxas
240 MacArthur Avenue, Hamilton QLD 4007, Australia
Patents
Microprojection arrays with enhanced skin penetrating properties and methods thereof
US-12090295-B2
View DetailsMicroprojection arrays with microprojections having large surface area profiles
US-11653939-B2
View DetailsCompact high mechanical energy storage and low trigger force actuator for the delivery of microprojection array patches (MAP)
US-11464957-B2
View Details
Microprojection arrays with enhanced skin penetrating properties and methods thereof
US-12090295-B2
View DetailsMicroprojection arrays with microprojections having large surface area profiles
US-11653939-B2
View DetailsCompact high mechanical energy storage and low trigger force actuator for the delivery of microprojection array patches (MAP)
US-11464957-B2
View DetailsProducts
High-density microarray patch vaccine delivery platform
A vaccine delivery platform consisting of a small patch with thousands of microscopic projections coated with dried vaccine, integrated into a single-use applicator for short-duration skin application to deliver antigen to skin-resident immune cells.
High-density microarray patch vaccine delivery platform
A vaccine delivery platform consisting of a small patch with thousands of microscopic projections coated with dried vaccine, integrated into a single-use applicator for short-duration skin application to deliver antigen to skin-resident immune cells.
Services
Aseptic production and batch manufacturing of combination patch-and-applicator products in GMP-capable facilities to support clinical supply and scale-up.
Design, conduct and support of early-stage clinical trials (safety, tolerability, immunogenicity) for vaccines delivered via microarray patches.
Formulation development for dried vaccine coatings, stability testing at elevated temperatures, and analytical method development to support regulatory submissions.
Design and engineering of applicator devices, automation and transfer of prototype processes into scalable manufacturing lines.
Commercial licensing of the patch platform to pharmaceutical companies and collaboration on co-development programs; in-licensing of vaccine antigens for platform integration.
Aseptic production and batch manufacturing of combination patch-and-applicator products in GMP-capable facilities to support clinical supply and scale-up.
Design, conduct and support of early-stage clinical trials (safety, tolerability, immunogenicity) for vaccines delivered via microarray patches.
Formulation development for dried vaccine coatings, stability testing at elevated temperatures, and analytical method development to support regulatory submissions.
Design and engineering of applicator devices, automation and transfer of prototype processes into scalable manufacturing lines.
Commercial licensing of the patch platform to pharmaceutical companies and collaboration on co-development programs; in-licensing of vaccine antigens for platform integration.
Expertise Areas
- Microarray patch vaccine delivery
- Vaccine formulation and thermostability
- Clinical trial management for early‑stage vaccine studies
- GMP biomanufacturing and aseptic processing
Key Technologies
- High-density microarray patches (microprojection patches)
- Dry-coating / crystalline vaccine formulations
- Thermostable vaccine formulations (ambient stability testing)
- Single-use applicator devices for transdermal delivery
News & Updates
Vaxxas has secured a US patent for its needle-free vaccination manufacturing technology, supporting its development of innovative vaccine delivery solutions.
Vaxxas received funding from Wellcome to conduct clinical studies on a typhoid vaccine delivered via its HD-MAP platform, aiming to improve thermostability and global access.
Vaxxas produced its 100th batch of needle-free vaccine patches at the Translational Research Institute in Brisbane, marking a significant step towards commercial manufacturing.
Vaxxas has secured a US patent for its needle-free vaccination manufacturing technology, supporting its development of innovative vaccine delivery solutions.
Vaxxas received funding from Wellcome to conduct clinical studies on a typhoid vaccine delivered via its HD-MAP platform, aiming to improve thermostability and global access.
Vaxxas produced its 100th batch of needle-free vaccine patches at the Translational Research Institute in Brisbane, marking a significant step towards commercial manufacturing.